Drug Profile
Pegapamodutide - Transition Therapeutics
Alternative Names: LY2944876; OPK 88003; Oxyntomodulin analog - Eli Lilly and Company; TT-401Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; OPKO Health; Transition Therapeutics
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; Glucose modulators; Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 14 Sep 2021 LeaderMed Group and OPKO Health enters into joint venture for develop and commercialize pegapamodutide in Asia, China, Hong Kong, Taiwan and Macau
- 02 Mar 2021 Phase II development is still ongoing for Obesity in USA (OPKO Health website, March 2021)
- 02 Mar 2021 Phase II development is still ongoing for Type 2 diabetes mellitus in USA, Spain, Romania, Puerto Rico, Poland, Mexico and Greece (OPKO Health website, March 2021)